Drugs that contain Betrixaban
1. List of Bevyxxa drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7598276 | PORTOLA PHARMS INC | Pharmaceutical salts and polymorphs of a factor Xa inhibitor |
Nov, 2026
(3 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9555023 | PORTOLA PHARMS INC | Pharmaceutical salts and polymorphs of a factor Xa inhibitor |
Nov, 2026
(3 years from now) | |
| US8557852 | PORTOLA PHARMS INC | Methods of using crystalline forms of a salt of a factor Xa inhibitor |
Sep, 2028
(5 years from now) | |
| US8987463 | PORTOLA PHARMS INC | Methods of synthesizing factor Xa inhibitors |
Dec, 2030
(7 years from now) | |
| US8404724 | PORTOLA PHARMS INC | Unit dose formulations and methods of treating thrombosis with an oral factor Xa inhibitor |
Mar, 2031
(8 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jun 23, 2022 |
NCE-1 date: June, 2021
Market Authorisation Date: 23 June, 2017
Treatment: Prophylaxis of pulmonary embolism; Prophylaxis of deep vein thrombosis (dvt); Prophylaxis of venous thrombosis; Inhibiting coagulation
Dosage: CAPSULE;ORAL
More Information on Dosage
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic